A Multicenter, Open-Label, Phase 2 Trial Comparing Crizanlizumab Combined With Standard Therapy to Standard Therapy Alone on Renal Function in Patients With Sickle Cell Nephropathy (STEADFAST).
- DOI
- 10.1002/ajh.70447
- Published
- 2026 Oct
- Container
- American journal of hematology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1002/ajh.70447,
title = {A Multicenter, Open-Label, Phase 2 Trial Comparing Crizanlizumab Combined With Standard Therapy to Standard Therapy Alone on Renal Function in Patients With Sickle Cell Nephropathy (STEADFAST).},
author = {Ataga KI and Bartolucci P and Saraf SL and Derebail VK and Inati A and Lebensburger JD and DeBonnett L and Cancado RD and Sharpe CC},
year = {2026},
journal = {American journal of hematology},
doi = {10.1002/ajh.70447},
url = {https://doi.org/10.1002/ajh.70447}
}RIS
TY - JOUR TI - A Multicenter, Open-Label, Phase 2 Trial Comparing Crizanlizumab Combined With Standard Therapy to Standard Therapy Alone on Renal Function in Patients With Sickle Cell Nephropathy (STEADFAST). AU - Ataga KI AU - Bartolucci P AU - Saraf SL AU - Derebail VK AU - Inati A AU - Lebensburger JD AU - DeBonnett L AU - Cancado RD AU - Sharpe CC PY - 2026 JO - American journal of hematology DO - 10.1002/ajh.70447 UR - https://doi.org/10.1002/ajh.70447 ER -
APA
KI, A., P, B., SL, S., VK, D., A, I., JD, L., L, D., RD, C., & CC, S. (2026). A Multicenter, Open-Label, Phase 2 Trial Comparing Crizanlizumab Combined With Standard Therapy to Standard Therapy Alone on Renal Function in Patients With Sickle Cell Nephropathy (STEADFAST).. American journal of hematology. https://doi.org/10.1002/ajh.70447
Source records
- pubmed · retrieved 2026-09-25T10:33:26.000Z
- europe-pmc · retrieved 2026-09-25T10:33:26.736Z